10-K · April 28, 2026
BioLife Solutions' 2025 10-K reflects a period of strategic realignment resulting in significant top-line growth despite ongoing operational challenges. With revenue increasing notably and consistent gross margins, the…
Earnings analysis · 10-Q
BLFS earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
BioLife Solutions demonstrated a robust start to 2026 with a revenue of $27.5 million, marking a 25% increase compared to the prior year. The company reported an earnings per share (EPS) of $0.04, surpassing estimates…
Read full summary
BioLife Solutions demonstrated a robust start to 2026 with a revenue of $27.5 million, marking a 25% increase compared to the prior year. The company reported an earnings per share (EPS) of $0.04, surpassing estimates and contributing to a positive outlook despite slight declines in gross margin. Cash reserves decreased from $120.2 million at the end of 2025 to $111.5 million, influenced by investment activities and cash flow from operations.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
From revenue to operating profit
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $0.04
What stood out
-
Revenue Increased by 25%
Total revenue reached $27.5 million for Q1 2026, up from $22.05 million in Q1 2025.
-
EPS Beat Expectations
Diluted EPS improved to $0.04, exceeding the expected $0.02 by 100%.
-
Operating Margin Improvement
Despite slight margin compression, the operating margin improved to 7.9% from negative margins in previous quarters.
-
Cash Flow from Operations
While cash used in operating activities was $(0.5) million, this reflects previous cash flow dynamics rather than operational weaknesses.
-
Positive Interest Income Growth
Interest income increased by 52%, reaching $1.04 million, benefiting from higher investment returns.
-
Continued Investment in R&D
R&D expenses increased by 84% to $2.65 million, indicating strong commitment to innovation.
What to watch
-
Margin Compression
Gross margin decreased to 64% from 67% year-over-year, driven by a shift to lower-margin products.
-
Cash Reserves Decrease
Cash and cash equivalents dropped to $111.5 million from $120.2 million, raising liquidity concerns.
-
Operational Cash Flow Decline
Net cash used in operating activities changed from a positive $1.7 million in Q1 2025 to a negative $0.5 million in Q1 2026.
Management's outlook
Revenue guidance for 2026 remains reiterated at $112.5 million to $115 million, anticipating 17% to 20% growth compared to 2025.
Earlier filings 4
10-K · February 26, 2026
BioLife’s 2025 10‑K shows a company reshaping its portfolio (multiple divestitures) while growing product revenue and investing in biopreservation R&D (PanTHERA acquisition). Full‑year revenue improved materially versus…
10-Q · August 7, 2025
BioLife reported Q2 2025 total revenue of $25,421,000, up $5,706,000 (≈29%) versus Q2 2024, driven by product revenue growth. GAAP operating loss widened to $(16,643,000) (operating margin -65.5%) primarily due to a…
10-Q · May 8, 2025
BioLife Solutions reported significant revenue growth in Q1 2025 with total revenue of $23.941 million, marking an increase of 30.0% from $18.433 million year-over-year. The gross margin remained strong at 65.9%,…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.